AAFMAA Wealth Management & Trust LLC Decreases Stock Holdings in Stryker Co. (NYSE:SYK)

AAFMAA Wealth Management & Trust LLC lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 18.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,486 shares of the medical technology company's stock after selling 1,215 shares during the quarter. Stryker accounts for approximately 0.9% of AAFMAA Wealth Management & Trust LLC's investment portfolio, making the stock its 26th biggest holding. AAFMAA Wealth Management & Trust LLC's holdings in Stryker were worth $2,042,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of SYK. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $25,000. Capital A Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $26,000. Rakuten Securities Inc. increased its stake in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker during the 4th quarter worth approximately $30,000. Finally, BankPlus Trust Department purchased a new stake in shares of Stryker during the 4th quarter worth approximately $33,000. Institutional investors own 77.09% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK traded up $1.05 during mid-day trading on Friday, reaching $384.15. 709,048 shares of the company were exchanged, compared to its average volume of 1,331,290. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $146.63 billion, a PE ratio of 49.50, a PEG ratio of 2.93 and a beta of 0.91. The company's 50 day moving average price is $370.10 and its 200 day moving average price is $376.03.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period in the previous year, the firm posted $2.50 EPS. The firm's revenue was up 11.9% compared to the same quarter last year. Sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on SYK. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research note on Friday. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research note on Tuesday, March 4th. JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Roth Mkm raised their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $427.30.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.